Enhancement of Anti-tumor Activity of Expanded Natural Killer Cells Against Gd2(+) Osteosarcoma (Os) in Combination With Romidepsin (Hdac Inhibitor), Alt-803 (Il-15 Superagonist) and Dinutuximab

Authors

Yaya Chu, New York Medical CollegeFollow
J Tesoriero
Jeremy Rosenblum, New York Medical CollegeFollow
H Wong
D LeeFollow
Mitchell Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

May 2017

Journal Title

Cytotherapy

Department

Pediatrics

Second Department

Epidemiology and Community Health

Recommended Citation

Chu, Y., Tesoriero, J., Rosenblum, J., Wong, H., Lee, D., & Cairo, M. (2017). Enhancement of Anti-tumor Activity of Expanded Natural Killer Cells Against Gd2(+) Osteosarcoma (Os) in Combination With Romidepsin (Hdac Inhibitor), Alt-803 (Il-15 Superagonist) and Dinutuximab. Cytotherapy, 19 (5 Suppl.), S12-S13. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/20